Vaxil’s (VXL) anti-cancer drug, E-selectin (P-Esbp), has shown encouraging results in an experiment with mice.
E-selectin, invented by professor Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology from Ben-Gurion University of the Negev, is an important component in inflammation, metastasis and tumor growth processes.
David’s previous work demonstrated the efficacy of P-Esbp when combined with doxorubicin (P-Esbp-DOX) in prolonging the lives of tumor-bearing mice with both primary (Lewis lung carcinoma) and metastatic tumors (melanoma lung metastasis model).
In order to further establish the potential of P-Esbp-DOX for treating metastatic cancer, the company designed an in-vivo experiment in a mouse model of aggressive liver metastasis of colorectal tumors.
Preliminary results of this experiment demonstrate at day 45, 70% of animals (5/7) treated with a single dose of P-Esbp-DOX-FITC at day 4 post tumor implantation remain alive and 40% (3/7) appear tumor free. This is compared to 1/6 and 0/6 animals alive in the alternate treatment and control arms.
The company will finalize its report – including in-vivo imaging – in the coming month and will share data when available.
Vaxil Bio is an immunotherapy biotech company focused on targeting prominent cancer markers and infectious diseases.
Vaxil (VXL) is up by 10.53 per cent and is currently trading at $0.105 per share as of 1:46 pm ET.